Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
For Journalists

Want to Make an Appointment or Need Patient Information?

Contact UPMC at
1-800-533-UPMC (8762).

Go to Find a Doctor to search for a UPMC doctor.​

Pitt Researchers Developing Liver and Joint “Tissue Chips” to Better Predict Drug Safety

PITTSBURGH, July 27, 2012 – Researchers at the University of Pittsburgh School of Medicine have been awarded federal grants to create micro-models of the liver and an arthritic joint as part of a national effort to build 3-D chips of cells and tissues that could provide a more rapid and accurate method of predicting toxicity of experimental therapies, as well as foster greater understanding of myriad diseases.
Of the 17 projects being funded by the National Institutes of Health (NIH), two will be led by Pitt researchers and could receive more than $10 million over the next five years. NIH plans to commit up to $70 million over five years for the Tissue Chips for Drug Screening program, which was launched by its new National Center for Advancing Translational Sciences (NCATS). Other awardees include Johns Hopkins University, Harvard University and Duke University.
“Tissue chips could provide a more accurate and less expensive way of testing new drugs and reduce our reliance on animal studies, which often don’t reliably reflect toxicity profiles later seen during human testing,” noted Arthur S. Levine, M.D., senior vice chancellor for the health sciences and dean, Pitt School of Medicine. “It is terrific that our stellar scientists will be able to build two of these chips here and contribute to the evolution of drug testing.”
The Pitt projects are:
  • 3-D Micro-Liver: D. Lansing Taylor, Ph.D., Allegheny Foundation Professor of Computational and Systems Biology, and director, University of Pittsburgh Drug Discovery Institute, will lead a team at Pitt and Massachusetts General Hospital to create a three-dimensional microfluidic structure made entirely of human cells that will mimic the acinus, the smallest functional unit of the liver. The team also will develop a panel of sentinel “biosensor cells” that will indicate liver toxicity with exposure to different drugs.
  • The current gold standard of testing is not very gold,” Dr. Taylor said. “In humans, the liver plays a key role in processing drugs, and many experimental agents have failed in the late stages of human testing because preclinical studies didn’t predict their impact on the liver, along with other organs. This project aims to solve that problem so that we have greater success in drug discovery and development.”
  • 3-D Micro-Arthritic Joint System: Rocky Tuan, Ph.D., the Arthur J. Rooney Sr. Professor of Sports Medicine and executive vice chair for research, Department of Orthopaedic Surgery, will lead a team to create a tissue chip that includes stem cell-produced bone and cartilage cells that simulate joint surfaces to better understand how arthritis develops and how to prevent it.
  • This system will allow us to explore the effects of not only inflammatory molecules and the wear-and-tear of aging on the entire joint, but also mechanical injuries, such as a hit or a sprain, both immediately and over time in molecular detail, which is not feasible with existing techniques,” said Dr. Tuan, who also is director of the Center for Military Medicine Research, director of the Center for Cellular and Molecular Engineering in the Department of Orthopaedic Surgery, and co-director of the McGowan Institute for Regenerative Medicine.

According to NIH, the Tissue Chips program is the result of collaboration between NIH, the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration, and was established by the NIH’s Common Fund and the National Institute of Neurological Disorders and Stroke.

“Serious adverse effects and toxicity are major obstacles in the drug development process,” said Thomas R. Insel, M.D., NCATS acting director. “With innovative tools and methodologies, such as those developed by the Tissue Chips program, we may be able to accelerate the process by which we identify compounds likely to be safe in humans, saving time and money, and ultimately increasing the quality and number of therapies available for patients.”

Drs. Taylor and Tuan’s projects also will receive support from the University of Pittsburgh Clinical and Translational Science Institute.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

Pittsburgh, PA, USA |